Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer

被引：0
|
作者：
Schmoll, H.
Tabernero, J.
Nowacki, M.
Maroun, J.
Price, T.
Lim, R.
Van Cutsem, E.
de Braud, F.
Haller, D.
机构：
[1] Univ Halle Wittenberg, Halle, K1Y 4K7, Germany
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Warsaw 117548, Poland
[4] Ottawa Reg Canc Ctr, B-3000 Ottawa, ON, Canada
[5] Queen Elizabeth Hosp, Adelaide, SA, Australia
[6] Natl Univ Singapore Hosp, Singapore, 19104, Singapore
[7] Univ Hosp Gasthuisberg, Louvain, Belgium
[8] Ist Europeo Oncol, Milan, Italy
[9] Univ Penn, Philadelphia, PA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [21] 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage III colon cancer - Abstracts
    Twelves, C.
    Scheithauer, W.
    McKendrick, J.
    Nowacki, M.
    Seitz, J.
    Van Haze, G.
    Wong, A.
    Diaz-Rubio, E.
    Cassidy, J.
    EJC SUPPLEMENTS, 2007, 5 (06): : 1 - 1
  • [22] Economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes' C colon cancer in an Italian hospital setting
    Di Costanzo, F.
    Sobrero, A.
    Twelves, C.
    Cassidy, J.
    Douillard, J.-Y.
    Giuliani, G.
    Patel, K. K.
    Garrison, L. P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 192 - 192
  • [23] Phase III trial of capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV plus oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer(MCRC)
    Rothenberg, M.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J.
    Goel, R.
    Gollins, S.
    Siu, L.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2007, 18 : VII17 - VII18
  • [24] COST COMPARISON: CAPECITABINE plus OXALIPLATIN (XELOX) VS 5-FU/LV plus OXALIPLATIN (FOLFOX4) IN THE ADJUVANT TREATMENT OF PATIENTS WITH COLON CANCER (ACC)
    Winterhalder, R.
    Delmore, G.
    Hardegger, T.
    Urspruch, A.
    Hieke, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 201 - 202
  • [25] Capecitabine (X) versus bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Positive efficacy results of a phase III trial
    Fink, M
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 (09) : 620 - 621
  • [26] Capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results
    Rothenberg, M.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J.
    Goel, R.
    Gollins, S.
    Siu, L.
    Cunningham, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 238 - 239
  • [27] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in Germany
    Aballea, S.
    Frick, M.
    Diel, R.
    Rosenfeld, S.
    Huppertz, E.
    Sievert, M.
    Jourdan, S.
    Drummond, M.
    Weinstein, M. C.
    Reichardt, P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 182 - 183
  • [28] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the US
    Aballea, S
    Chancellor, J
    Raikou, M
    Drummond, M
    Weinstein, M
    Jourdan, S
    Carita, P
    Bridgewater, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 254S - 254S
  • [29] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK
    Aballea, S.
    Chancellor, J. V. M.
    Raikou, M.
    Drummond, M. F.
    Jourdan, S.
    Carita, P.
    Bridgewater, J.
    Boler, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
  • [30] Capecitabine vs. Bolus 5-FU/LV as adjuvant therapy for patients with Dukes' C colon cancer: Pharmacoeconomic evaluation of X-act trial data from Czech perspective
    Jiraskova, L.
    Dolezal, T.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
12345